<DOC>
	<DOC>NCT00275821</DOC>
	<brief_summary>The study will test if the efficacy and safety of an alternative dosing regimen is as effective as monthly injections.</brief_summary>
	<brief_title>Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patients with primary or recurrent subfoveal CNV secondary to AMD, including those with predominantly classic, minimally classic or occult lesions with no classic component Patients who have a BCVA score between 73 and 24 letters, inclusively, in the study eye using ETDRSlike grading charts (approximately 20/40 to 20/320) Prior treatment in the study eye with verteporfin, externalbeam radiation therapy, subfoveal focal laser photocoagulation, vitrectomy, or transpupillary thermotherapy. History of submacular surgery or other surgical intervention for AMD in the study eye, glaucoma filtration surgery, corneal transplant surgery. Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within one month preceding Baseline. Other protocoldefined inclusion/exclusion criteria applied to the study.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Age-related macular degeneration, ranibizumab</keyword>
</DOC>